Breast cancer has been the most common cancer worldwide in women in the past decade ([@bib4]). Many molecular target drugs against breast cancer have been examined in the recent years. The development of new drugs has resulted in longer overall survival for patients with human epidermal growth factor receptor type2 (HER2) type and luminal type of breast cancer. However, triple-negative breast cancer (TNBC) does not have a cell-surface protein, such as HER2, oestrogen receptor and progesterone receptor, that can be used as a target for a molecular target drug. Moreover, TNBC is generally characterised as having a high rate of distant metastasis and poor disease-specific survival compared with other breast cancer subtypes ([@bib20]).

Angiogenesis is one of the important hallmarks of cancer ([@bib24]), and it is vital for tumourigenesis and tumour development because tumours cannot grow \>2 mm in diameter without angiogenesis ([@bib26]) It is well-known that vascular endothelial growth factor (VEGF), which functions by binding to both VEGF receptors 1 and 2, is the master regulator of angiogenesis ([@bib24]). Recent studies have demonstrated that X-linked inhibitor of apoptosis-associated factor 1 ([@bib27]) and several miRNAs ([@bib8]; [@bib16]; [@bib12]; [@bib23]; [@bib7]; [@bib26]) are associated with angiogenesis. It had also been shown that patients treated with bevacizumab, an antibody against VEGF, had longer overall survival than that of patients not treated with bevacizumab ([@bib21]). Thus, a strategy for decreasing the amount of VEGF secretion from a tumour is promising for treatment of breast cancer.

Endoplasmic reticulum disulfide oxidase 1-*α* (ERO1-*α*) is an oxidase located in the endoplasmic reticulum. Recently, we have shown that ERO1-*α* is present in high levels in various types of tumours, and that ERO1-*α* is a poor prognosis factor of breast cancer ([@bib15]). However, how ERO1-*α* affects tumour growth *in vivo* and why patients who have a tumour with a high expression level of ERO1-*α* have a poor prognosis are still unknown.

In this study, we found that expression of ERO1-*α* was the poor prognosis factor in TNBC and that the expression of ERO1-*α* correlated with the secretion of VEGF and angiogenesis in *in vivo* tumour models and clinical cases. The results of our study suggest that ERO1-*α*-targeted therapy such as knockdown of ERO1-*α* or blockade of ERO1-*α* function will be an effective strategy for cancer.

Materials and methods
=====================

Cells and agents
----------------

The human breast cancer lines MDA-MB-157, MDA-MB-231, MDA-MB-468 and MCF7, the human pancreas cancer cell line MIAPaCa2 and the human gastric cancer cell line MKN45 were purchased from ATCC (Manassas, VA, USA). MDA-MB-157 cells were cultured in Roswell Park Memorial Institute-1640 (Sigma-Aldrich, St Louis, MO, USA) and MDA-MB-231, MDA-MB-468, MCF7, MIAPaCa2 and MKN45 cells were cultured in Dulbecco\'s modified Eagle\'s medium (DMEM; Sigma-Aldrich) supplemented with 10% fetal calf serum (FCS) at 37 °C in 5% CO~2~. Short-hairpin RNA for human ERO1-*α* (TR313168) was purchased from OriGene (Rockville, MD, USA) and transfected to MDA-MB-231, MCF7 and MIAPaCa2 cells using Lipofectamine 2000 (Life Technologies, Carlsbad, CA, USA). To establish cells with ERO1-*α*-overexpression, MDA-MB-231 cells were transfected with human ERO1-*α* cDNA using Lipofectamine 2000 (Life Technologies) as per the manufacturer\'s instructions. Cells were stably propagated under puromycin selection (1 or 2 *μ*g ml^−l^). The ERO1-*α* inhibitor EN460 was purchased from Millipore (Billerica, MA, USA).

*In vivo* study
---------------

Female non-obese diabetic--severe combined immunodeficient (NOD/SCID) mice, 4 weeks old, were obtained from Sankyo Laboratory Co. Ltd. (Tsukuba, Japan) and used at 5 weeks of age. Studies were performed with approval of the Animal Experiment Ethics Committee of Sapporo Medical University (Sapporo, Japan). For tumour-formation studies, mice were injected with 1 × 10^6^ MDA-MB-231 cells, ERO1-*α*-overexpressed (OE) cells or ERO1-*α* knockdown (KD) cells into the right fourth mammary glands. Tumour growth was measured 2--3 times per week in two dimensions, and tumour volume was calculated using the formula 3.14 × (width^2^ × length)/6. Tumour length and width were measured with a pair of calipers.

Real-time PCR analysis
----------------------

Total RNA was isolated from cultured cells and normal breast tissues using Isogen reagent (Nippon Gene, Tokyo, Japan) and RNeasy Mini kits (QIAGEN, Valencia, CA, USA) according to the manufacturers\' instructions. The cDNA mixture was synthesised from 1 *μ*g total RNA by reverse-transcription using Superscript III and oligo (dT) primer (Life Technologies) according to the manufacturer\'s protocol. Real-time polymerase chain reaction (real-time PCR) was performed to determine the expression levels of ERO1-*α*, VEGF and *β*-actin. Expression values for each sample were normalised to *β*-actin, and fold levels of the indicated genes represent the mean (±s.e.m.) of replicate reactions. Primer sequences were as follows: *β*-actin (ACTB), Hs01060665_g1; ERO1-*α* (ERO1L), Hs00205880_m1; and VEGF, Hs00900055_m1 (Life Technologies). PCR cycles were performed on the StepOne Real-Time PCR System (Life Technologies) with the following cycle conditions: 2 min at 50 °C, 10 min at 95 °C, 45 cycles of 15 s at 95 °C and 1 min at 60 °C. The delta--delta Ct method was used for data analysis.

Western blot analysis
---------------------

ERO1-*α* recombinant protein was purchased from Abnova (Taipei, Taiwan). BSA was purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). Normal breast tissue extract was purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Cultured cells were washed in ice-cold phosphate-buffered saline (PBS), lysed by incubation on ice in a lysis buffer (50 mmol l^−1^ Tris-HCl (pH 7.5, 150 mmol l^−1^ NaCl, 5 mmol l^−1^ EDTA, 1% NP40), and cleared by centrifugation at 21 880 **g** for 30 min at 4 °C. For blockade of free thiols, cells were pretreated for 5 min with 10 mM methyl methanethiosulfonate (MMTS; Pierce, Rockford, IL, USA) in PBS. Post-nuclear supernatants were divided and heated for 5 min at 95 °C in a non-reducing or reducing sodium dodecyl sulfate (SDS) sample buffer, resolved by SDS-PAGE and electrophoretically transferred to PVDF membranes (Immobilon-P; Millipore). The membranes were incubated with blocking buffer (5% non-fat dried milk in PBS) for 30 min at room temperature and then incubated overnight with anti-ERO1-*α* mAb (Abnova), anti-HIF mAb (BD, San Jose, CA, USA), anti-VEGF polyclonal antibody (Santa Cruz Biotechnology), or mouse anti-*β*-actin mAb AC-15 (Sigma-Aldrich). After washing three times with wash buffer (0.05% Tween-20 in Tris-buffered saline), the membranes were reacted with peroxidase-labelled goat anti-mouse IgG antibody or peroxidase-labelled goat anti-rabbit IgG antibody (KPL, Gaithersburg, MD, USA) for 3 h. Finally, the signal was visualised using an ECL detection system (Amersham Life Science, Arlington Heights, IL, USA) according to the manufacturer\'s protocol.

Analysis of reactive oxygen species level
-----------------------------------------

Cells were collected by trypsinization, washed with DMEM twice, resuspended in FCS-free DMEM with 10 *μ*M of 5-(and-6)-chloromethyl-2′,7′-dichlorofluorescine diacetate, acetyl ester (CM-H~2~DCFDA; Life Technologies), and incubated at 37 °C for 30 min in the dark. Then fluorescence intensity was determined by using a FACSCalibur flow cytometer (BD) and FlowJo (Tree Star Inc., Ashland, OR, USA).

Immunohistochemistry
--------------------

Tissue was fixed in neutral 10% buffered formaldehyde, embedded in paraffin and cut into 5-*μ*m-thick slices for ERO1-*α* staining and CD31 staining. Reactivity of the anti-ERO1-*α* mAb was determined by perinuclear staining within tumour cells, indicating endoplasmic reticulum localisation. Anti-CD31 polyclonal antibody, which was used for staining of blood vessels in tumour tissues obtained from mice, was purchased from Abcam (Cambridge, MA, USA).

Enzyme-linked immunosorbent assay
---------------------------------

MDA-MB-231 cells were plated at 2 × 10^5^ cells in a 10-cm dish and were incubated for 4 days. In the study using the ERO1-*α* inhibitor EN460, MDA-MB-231 cells were plated at 5 × 10^5^ cells per well in 6-well plates and were incubated with 0--12.5 *μ*M EN460 for 24 h. MCF7 and MIAPaCa2 cells were plated at 1 × 10^5^ cells per well in 6-well plates and were incubated for 24 h. SiRNA for human ERO1-*α* (SR309340) was purchased from OriGene and transfected to MDA-MB-157 and MKN45 cells using RNAiMAX (Life Technologies). After 3 days, MDA-MB-157 and MKN45 Cells were plated at 1 × 10^5^ cells per well in 6-well plates and were incubated for 24 h. All samples were stored at −80 °C until assayed. Human VEGF (R&D Systems, Minneapolis, MN, USA) levels were measured using a sandwich enzyme-linked immunosorbent assay (ELISA) kit. Absorbance was determined at 450 nm.

Patients
--------

Tissue samples were obtained from 56 patients diagnosed with TNBC from 2004 to 2010 at Sapporo Medical University Hospital. A total of 56 specimens of primary invasive carcinoma were obtained from resected tumours. Other background data for the patients are shown in the [Supplementary Table 1](#sup1){ref-type="supplementary-material"}. The expression of aldehyde dehydrogenase-1 (ALDH1) and ERO1-*α* was determined immunohistochemically in paraffin-embedded tissue specimens. A mAb against CD31 was purchased from Leica Biosystems (Nussloch, Germany), and a mAb against ALDH1 was purchased from BD. The expression status of ERO1-*α* was graded as described by [@bib15]): score 0 (positive cells 0%), score 1 (positive cells\<10%), score 2 (10%⩾positive cells⩽30%), score 3 (positive cells\>30%). Total populations of score 1 were included as the ERO1-*α* reduced group and score 2 and score 3 were regarded as the ERO1-*α* positive group. The expression status of ALDH1 was graded by our original classification: score 0 (positive cells 0%), score 1 (positive cells\<0.5%), score 2 (0.5%⩾positive cells⩽2.0%), score 3 (positive cells\>2.0%). Histological examinations were carried out on slides with paraffin-embedded samples stained by H&E according to the criteria of the Japanese Breast Cancer Society, which are based on the International Union against Cancer TMN classification criteria.

Statistical analysis
--------------------

Student\'s *t*-test was used for the analysis of two unpaired samples. Statistical differences in results of the study *in vivo* were analysed by Student\'s *t*-test and Mann--Whitney\'s *U*-test. Overall survival rates were calculated by the Kaplan--Meier method, and differences in survival curves were assessed by the log-rank test. The Cox-proportional hazards model was used for multivariate analysis. Tukey\'s test was used for the analysis of the number of blood vessels in clinical case. All analyses were carried out with STATMATE version 3.19 (ATMS Co., Ltd., Tokyo, Japan) and SPSS version 18.0 (SPSS Inc., Chicago, IL, USA). A *P*\<0.05 was regarded as statistically significant. All statistical tests were two-sided.

Results
=======

Expression of ERO1-*α* is a poor prognosis factor for TNBC
----------------------------------------------------------

We have reported that the expression of ERO1-*α* within a tumour is a poor prognosis factor in breast carcinoma ([@bib15]). To further examine the effect of ERO1-*α* on TNBC, we classified clinical cases (*n*=56) into 4 groups based on the expression of ERO1-*α* (Figure 5A). In univariate survival analysis, patients with ERO1-*α* 2+ or 3+ had significantly shorter overall survival than that of patients with ERO1-*α* 0 or 1+ ([Figure 1](#fig1){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}). In multivariate analysis of overall survival by Cox regression analysis, tumour stage and expression of ERO1-*α* were independent prognosis factors ([Table 1](#tbl1){ref-type="table"}).

Expression of ERO1-*α* in TNBC cell lines, TNBC tissues and normal breast tissues
---------------------------------------------------------------------------------

We have reported that the expression of ERO1-*α* was enhanced in a variety of cancer cells ([@bib15]). To determine the expression of ERO1-*α* in TNBC, we used antibodies specific to ERO1-*α*. The specificity of ERO1-*α* antibody for immunohistochemistry was shown by [@bib13]). In addition, we examined the specificity of ERO1-*α* antibody for Western blotting analysis by using ERO1-*α* recombinant protein and BSA. As shown in [Supplementary Figure 1](#sup1){ref-type="supplementary-material"}, we confirmed that the mAb to ERO1-*α* specifically recognised the recombinant ERO1-*α* protein. These results indicated that the mAb to ERO1-*α* used in the present study was specific for ERO1-*α* protein.

In TNBC cell lines and TNBC tissues, the expression of ERO1-*α* was upregulated compared with the expression of ERO1-*α* in normal breast tissue at the mRNA ([Figure 2A](#fig2){ref-type="fig"}) and protein levels ([Figure 2B](#fig2){ref-type="fig"}). Immunohistochemical staining also showed that ERO1-*α* was overexpressed in tumour cells but not in normal breast tissue ([Figure 2C and D](#fig2){ref-type="fig"}).

Expression of ERO1-*α* in MDA-MB-231 cells promotes tumour growth via promoting angiogenesis
--------------------------------------------------------------------------------------------

To examine the role of ERO1-*α* in tumour growth, we established ERO1-*α* knockdown TNBC MDA-MB-231 (sh221 and sh222) cells by using shRNA against ERO1-*α* ([Figure 3A](#fig3){ref-type="fig"}). When NOD/SCID mice were challenged with MDA-MB-231 cells transfected with scrambled shRNA (SCR cells) and KD cells, we observed that KD cells caused retardation of tumour growth, whereas wild-type and SCR cells did not ([Figure 3B](#fig3){ref-type="fig"}). We then investigated the mechanism by which knockdown of ERO1-*α* caused retardation of tumour growth. Immunohistochemistorical analysis showed that knockdown of ERO1-*α* decreased the number of CD31^+^ blood vessels within tumours per high-power field ([Figure 3C](#fig3){ref-type="fig"} and [Supplementary Figure 2A](#sup1){ref-type="supplementary-material"}). Previous studies demonstrated that a decrease in the number of blood vessels causes retardation of *in vivo* tumour growth as shown in [Figure 3C](#fig3){ref-type="fig"} from results of the present study ([@bib6]; [@bib25]; [@bib14]). Thus, ERO1-*α* expression in cancer cells facilitated tumour angiogenesis (neovascularization), thereby resulting in the promotion of tumour growth. To further examine the effect of ERO1-*α* on tumour growth and angiogenesis, we established ERO1-*α*-overexpressed (9A3, 9C1 and 9C2) cell lines by introducing human cDNA of ERO1-*α* ([Figure 3D](#fig3){ref-type="fig"}). When NOD/SCID mice were challenged with mock cells and with 9A3, 9C1 and 9C2 cells, we observed that all of the OE tumours grew more aggressively than the mock tumour did ([Figure 3E](#fig3){ref-type="fig"}). To investigate the mechanism by which the OE tumour grew more aggressively than the mock tumour did, the tumours were stained for CD31. Immunohistochemical analysis showed that overexpression of ERO1-*α* increased the number of CD31^+^ blood vessels per high-power field ([Figure 3F](#fig3){ref-type="fig"} and [Supplementary Figure 2B](#sup1){ref-type="supplementary-material"}). These results again suggested that the expression of ERO1-*α* promoted tumour angiogenesis.

Knockdown of ERO1-*α* inhibits secretion of VEGF by inhibition of oxidative protein folding
-------------------------------------------------------------------------------------------

Overexpression of ERO1-*α* augments secretion of VEGF not only by promoting oxidative protein folding but also by increasing mRNA expression of VEGF. MDA-MB-231 cells secreted a large amount of VEGF. To examine the effect of ERO1-*α* on secretion of VEGF, we measured the amounts of VEGF produced by SCR and KD cells using ELISA. We observed that SCR cells produced a larger amount of VEGF than the KD cells ([Figure 4A](#fig4){ref-type="fig"}). Previous studies demonstrated that the number of blood vessels was decreased by a reduction in the amount of VEGF production as shown in [Figure 4A](#fig4){ref-type="fig"} from results of the present study ([@bib6]; [@bib25]; [@bib14]). To confirm these findings, we examined the effect of ERO1-*α* knockdown using various types of cancer cell lines (breast cancer cell lines MDA-MB-157 and MCF7, pancreatic cancer cell line MIAPaCa2 and gastric cancer cell line MKN45). We further found that control cells produced a larger amount of VEGF than the ERO1-*α* knockdown cells by using MCF7, MDA-MB-157, MIAPaCa2 and MKN45 cells ([Supplementary Figure 3A--H](#sup1){ref-type="supplementary-material"}). To determine the effect of ERO1-*α* on VEGF mRNA expression level, we compared VEGF mRNA expression levels by real-time RT-PCR. VEGA mRNA expression levels were not different in SCR cells and KD cells ([Figure 4B](#fig4){ref-type="fig"}). In addition, VEGA mRNA expression levels were not different in control cells and ERO1-*α* knockdown cells when we used MCF7, MDA-MB-157, MIAPaCa2 and MKN45 cells ([Supplementary Figure 3I--L](#sup1){ref-type="supplementary-material"}). As ERO1-*α* is known to act as an oxidoreductase, we investigated the redox states of VEGF in SCR cells and KD cells by Western blot analysis under a non-reducing condition using MMTS. We found that the ratio of the oxidised form (mature form) to the reduced form (immature form) of VEGF in KD cells was lower than that in SCR cells under a non-reducing condition ([Figure 4C and D](#fig4){ref-type="fig"}). Moreover, we found that the total amount of VEGF protein in KD cells decreased under a reducing condition compared with the total amount in SCR cells. We speculated that the reduction in the total amount of VEGF protein in KD cells depended on degradation via ER-associated degradation. This will be examined in the future. To further examine the effect of ERO1-*α* on production of VEGF, we treated MDA-MB-231 cells with the ERO1-*α* inhibitor EN460. When we compared non-treated MDA-MB-231 cells with MDA-MB-231 cells that had been treated with EN460, we observed that the non-treated MDA-MB-231 cells produced a larger amount of VEGF than the treated MDA-MB-231 cells ([Figure 4E](#fig4){ref-type="fig"}). However, EN460 treatment did not affect the mRNA levels of VEGF ([Figure 4F](#fig4){ref-type="fig"}). It has been shown that VEGF has inter- and intra-molecular disulfide bonds ([@bib19]) and that disulfide bond formation is required for VEGF to exert its biological activity. Taking this into account, these results indicated that tumour ERO1-*α* has a pivotal role in the generation of disulfide bonds within VEGF at the post-transcriptional level. On the other hand, when we examined the amounts of VEGF secreted by mock cells and all of the OE cells, we found that the amounts of VEGF secreted by all of OE cells was larger than that secreted by the mock cells ([Figure 4G](#fig4){ref-type="fig"}). As ERO1-*α* is known to act as an oxidoreductase, we investigated the redox states of VEGF in mock cells and OE cells by Western blot analysis under a non-reducing condition using MMTS. We found that the ratio of the oxidised form (mature form) to the reduced form (immature form) of VEGF in OE cells was higher than that in mock cells under a non-reducing condition ([Figure 4I and J](#fig4){ref-type="fig"}). Next, when we examined the effect of ERO1-*α* on VEGF mRNA expression levels, we found that the VEGF mRNA level in all of the OE cells was significantly higher than that in mock cells ([Figure 4H](#fig4){ref-type="fig"}). Because the VEGF mRNA expression level was enhanced by hypoxia-inducible factor 1*α* (HIF-1*α*) ([Supplementary Figure 4](#sup1){ref-type="supplementary-material"}), we compared the expression levels of HIF-1*α* protein in mock cells and all of the OE cells. We found that the expression of HIF-1*α* protein in OE cells was enhanced ([Figure 4K](#fig4){ref-type="fig"}). It is well-known that HIF-1*α* protein is accumulated by reactive oxygen species (ROS). Therefore, we examined the ROS levels in mock cells and OE cells. We found that ROS levels in OE cells were significantly increased compared with those in mock cells ([Figure 4L and M](#fig4){ref-type="fig"}). These results suggested that ERO1-*α* influenced not only protein oxidative folding of VEGF but also VEGF mRNA expression via accumulation of HIF-1*α* by ROS which ERO1-*α* produced.

Expression of ERO1-*α* correlates with angiogenesis in clinical cases
---------------------------------------------------------------------

TNBCs were stained for ERO1-*α* and were categorised into 4 groups (scores of 0--3+ [Figure 5A](#fig5){ref-type="fig"}). Immunohistochemical staining for CD31 showed that differences in the numbers of CD31^+^ blood vessels in ERO1-*α* score 0, score 1+, 2+ and score 3+ tumours ([Supplementary Figure 5](#sup1){ref-type="supplementary-material"}). Quantification analysis showed that the expression of ERO1-*α* correlated with the number of blood vessels ([Figure 5B](#fig5){ref-type="fig"}).

Discussion
==========

Most of the proteins that are secreted by cells or expressed on the cell-surface have intra- and/or inter-molecular disulfide bonds. These disulfide bonds are required for proper protein function. Thus, oxidative protein folding is critical for normal cell function and homoeostasis. Among the oxidoreductases expressed in the endoplasmic reticulum, ERO1-*α* is central to oxidative protein folding, but its expression varies in a tissue-specific manner ([@bib15]). Furthermore, we previously showed that ERO1-*α* is overexpressed in various types of cancer cells and cancer tissues ([@bib15]) and influences the formation of disulfide bonds of granulocyte colony-stimulating factor, CXC chemokine ligands 1 and 2 ([@bib22]). It is known that the formation of a disulfide bond by ERO1-*α* is accompanied by the production of ROS such as hydrogen peroxide (H~2~O~2~; [@bib2]; [@bib10]). When we compared ROS levels in mock cells and OE cells, we found that ROS level in OE cells was higher than that in mock cells. Moreover, it has been shown that ROS induce stabilisation of HIF-1*α* protein through inhibition of prolyl hydroxylase enzyme function ([@bib2]; [@bib11]; [@bib3]; [@bib10]; [@bib5]; [@bib18]). As a result, HIF-1*α* accompanied by HIF-1*α* binds to hypoxic response elements of target genes ([@bib17]; [@bib9]; [@bib1]; [@bib18]). Our results suggested that ROS, which are products of ERO1-*α*-mediated oxidative folding, upregulate the mRNA expression of VEGF via stabilisation of HIF-1*α* protein.

VEGF is a covalent homodimeric protein with three intramolecular disulfides in each polypeptide chain and with two inter-chain disulfide bonds covalently joining the two identical monomers ([@bib19]). MDA-MB-231 tumour cells secreted a large amount of VEGF. In contrast, ERO1-*α* knockdown cells showed decreased secretion of VEGF. Therefore, we hypothesised that ERO1-*α* is also involved in the proper oxidative protein folding of VEGF before it is secreted, and that the loss of ERO1-*α* leads to decreased production of functionally active VEGF as shown by Western blotting under a non-reducing condition ([Figure 4C](#fig4){ref-type="fig"}). To further confirm that what we observed is a post-transcriptional event, we conducted real-time RT-PCR on SCR and KD cells. We did not observe differences in mRNA levels of VEGF among the three cell lines, suggesting that ERO1-*α* acted at the post-translational level.

We showed that ERO1-*α* contributed to angiogenesis by augmentation of VEGF production at the protein level and mRNA level. We could not determine whether ERO1-*α* directly formed a mixed disulfide intermediate with VEGF or whether ERO1-*α* cooperated with protein disulfide isomerase to produce disulfide bonds within VEGF in the ER. These questions need to be clarified. Although further studies are needed to understand the role of ERO1-*α in vivo*, the results presented here strongly suggest that targeted inhibition of ERO1-*α* is a promising strategy for treatment of breast cancer.
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![**Kaplan--Meier analysis of overall survival for ERO1-*α* expression in 56 cases of invasive TNBC.**   ](bjc2016105f1){#fig1}

![**Expression of ERO1-*α* in TNBC tissue was enhanced compared with that in normal breast tissue.** (**A**) Human ERO1-*α* mRNA levels in TNBC cell lines, TNBC tissues and normal breast tissue determined by real-time PCR. (**B**) Western blot analysis of TNBC cell lines, TNBC tissue and normal breast tissue. (**C**) Normal breast tissue and (**D**) TNBC tissue were stained for ERO1-*α* ( × 100, inset: × 200). \**P*\<0.05, unpaired Student\'s *t*-test.](bjc2016105f2){#fig2}

![**Expression of ERO1-*α* promoted tumour growth via augmenting angiogenesis.** (**A**) Western blot analysis of MDA-MB-231 (wild-type (WT)) cells, scrambled shRNA-transfected (SCR) cells and ERO1-*α* knockdown (sh221 and sh222) cells. (**B**) Tumour growth rates of SCR, sh221 and sh222 cells were compared in NOD/SCID mice (five animals per group). (**C**) The numbers of blood vessels within SCR and KD cells per high-power field were compared. (**D**) Western blot analysis of mock cells and ERO1-*α*-overexpressed (9A3, 9C1 and 9C2) cells. (**E**) Tumour growth rates of mock, 9A3, 9C1 and 9C2 cells were compared in NOD/SCID mice (five animals per group). (**F**) The numbers of blood vessels within mock cells and OE cells per high-power field were compared. ^\#^*P*\<0.001, Mann--Whitney\'s *U*-test. \**P*\<0.01, \*\**P*\<0.001, unpaired Student\'s *t*-test.](bjc2016105f3){#fig3}

![**ERO1-*α* influenced the VEGF secretion via both promoting disulfide formation and the mRNA expression level.** (**A**) Concentrations of VEGF in the 24-h culture supernatants from SCR, sh221 and sh222 cells were measured using ELISA. (**B**) VEGF mRNA expression levels in SCR, sh221 and sh222 cells were determined by real-time PCR analysis. (**C**, **D**) Redox status of VEGF in SCR and KD cells was examined by Western blotting under reducing (R) or non-reducing (NR) conditions. Reduced form (R) and oxidised form (O) of VEGF are indicated. The ratio of the oxidised form (O) and reduced form (R) obtained in SCR cells was set as 1, and the differences in the ratio of the oxidised form (O) and reduced form (R) induced by sh221 cells were plotted. (**E**) Concentrations of VEGF in the 24-h culture supernatants from non-treated MDA-MB-231 cells and MDA-MB-231 cells treated with an ERO1-*α* inhibitor were measured using ELISA. (**F**) VEGF mRNA expression levels in non-treated MDA-MB-231 cells and MDA-MB-231 cells treated with an ERO1-*α* inhibitor were determined by real-time PCR analysis. (**G**) Concentrations of VEGF in the 24-h culture supernatants from mock, 9A3, 9C1 and 9C2 cells were measured using ELISA. (**H**) VEGF mRNA expression levels in mock, 9A3, 9C1 and 9C2 cells were determined by real-time PCR analysis. (**I**, **J**) Redox status of VEGF in mock and OE cells was examined by Western blotting under reducing (R) or non-reducing (NR) conditions. Reduced form (R) and oxidised form (O) of VEGF are indicated. The ratio of the oxidised form (O) and reduced form (R) obtained in mock cells was set as 1, and the differences in the ratio of the oxidised form (O) and reduced form (R) induced by 9C2 cells were plotted. (**K**) Western blot analysis of mock, 9A3, 9C1 and 9C2 cells. (**L**, **M**) The amount of ROS in 9C2 (bold line) cells was compared with that in mock (thin line) cells. Dotted line and dashed line show unstained cells. The mean fluorescence intensity (MFI) value obtained in mock cells was set as 1, and the differences in MFI induced by 9C2 cells were plotted. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001, unpaired Student\'s *t*-test (*vs* control).](bjc2016105f4){#fig4}

![**Expression of ERO1-*α* in TNBC was involved in angiogenesis in clinical cases.** (**A**) TNBCs were classified into four groups by stainability for ERO1-*α*. (**B**) The correlations of TNBCs with expression of ERO1-*α* and numbers of blood vessels were examined. The *P*-values are given for differences in median values. \**P*\<0.05, \*\**P*\<0.001, Tukey\'s test.](bjc2016105f5){#fig5}

###### Univariate and multivariate survival analyses in TNBC patients (*n*=56)

  **Items**                            **Contents**    **HR**    **95% CI**    ***P-*****value**
  ------------------------------------ -------------- -------- -------------- -------------------
  **Univariate survival analysis**                                            
  Age                                  \<60 years        1                              
                                       60--69 years     2.17     0.61, 7.70          0.23
                                       ⩾70 years        2.41     0.60, 9.73          0.218
                                       Total                                         0.157
  Basal                                Non-basal         1                            ---
                                       Basal            5.92    0.77, 45.63          0.088
                                       Total                                          ---
  Stage                                I or II           1                            ---
                                       III              3.66    0.94, 14.17          0.061
                                       IV              10.09    2.55, 39.93          0.001
                                       Total                                        \<0.001
  ALDH1                                (−)               1                            ---
                                       (1+)             2.02    0.37, 11.02          0.418
                                       (2+)             3.6     0.51, 25.64          0.201
                                       (3+)             2.08    0.35, 12.45          0.423
                                       Total                                         0.386
  ERO1-*α*                             (−) or (1+)       1                            ---
                                       (2+)             4.95    0.91, 27.06          0.065
                                       (3+)             5.99    1.09, 32.76          0.039
                                       Total                                         0.029
  **Multivariate survival analysis**                                          
  Stage                                I or II           1                              
                                       III              1.79     0.35, 9.26          0.489
                                       IV              14.92    2.20, 101.09         0.006
                                       Total                                         0.011
  ERO1-*α*                             (−) or (1+)       1                            ---
                                       (2+)             6.69    1.01, 44.15          0.048
                                       (3+)             5.99    1.05, 36.23          0.044
                                       Total                                         0.041

Abbreviations: ALDH1=aldehyde dehydrogenase-1; CI=confidence interval; ERO1-*α*=endoplasmic reticulum disulfide oxidase 1-*α*; HR=hazard ratio.
